STOCK TITAN

Pasithea Therapeutics Corp - KTTAW STOCK NEWS

Welcome to our dedicated news page for Pasithea Therapeutics (Ticker: KTTAW), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pasithea Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pasithea Therapeutics's position in the market.

Rhea-AI Summary
Pasithea Therapeutics Corp. to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.2%
Tags
conferences
-
Rhea-AI Summary
Pasithea Therapeutics Corp. (NASDAQ: KTTA) announced a publication in the Proceedings of the National Academy of Sciences related to its PAS-003 drug discovery program targeting α5/β1 integrin for the treatment of amyotrophic lateral sclerosis (ALS). The study reveals increased integrin expression in ALS patient tissues, specificity of α5 integrin in ALS, and the efficacy of a monoclonal antibody against α5 integrin in improving survival and motor function in the SOD1G93A mouse model of ALS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
none
-
Rhea-AI Summary
Pasithea Therapeutics Corp. announces a $4.0 million tender offer to repurchase up to 5.7 million shares of its common stock at $0.70 per share. The offer is expected to close in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.9%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.9%
Tags
none
-
Rhea-AI Summary
Pasithea Therapeutics Corp. confirms that its Board of Directors has formed a special committee to evaluate an unsolicited proposal from Lucy Scientific Discovery Inc. to acquire all outstanding shares of Pasithea common stock. The committee is actively evaluating the proposal.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
management
-
Rhea-AI Summary
Pasithea Therapeutics Corp. has completed manufacturing of GMP-compliant Phase 1 clinical supplies of its lead product candidate PAS-004, a next-generation macrocyclic MEK Inhibitor. The company expects to file an IND application with the FDA in the second half of 2023 and plans to initiate a Phase 1 clinical trial by the end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.11%
Tags
none
Rhea-AI Summary
Pasithea Therapeutics Corp. has received an unsolicited proposal from Lucy Scientific Discovery Inc. to acquire all outstanding shares of Pasithea common stock. The proposal includes $0.60 in cash plus $0.25 worth of Lucy common stock per share. Pasithea's Board of Directors will review and evaluate the proposal to determine the best course of action.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Pasithea Therapeutics Corp. to participate in EF Hutton Global Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
conferences
Pasithea Therapeutics Corp

Nasdaq:KTTAW

KTTAW Rankings

KTTAW Stock Data

754.00k
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Miami Beach